Patents
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
12/2007
12/27/2007WO2007147816A1 Insulinotropic peptide synthesis
12/27/2007WO2007147590A2 Solution and method to reduce, treat and/or prevent oxidative stress and cell activation
12/27/2007WO2007147265A1 Polynucleotides and polypeptide sequences involved in cancer
12/27/2007WO2007133476A3 Competitive substrate inhibition to increase drug bioavailability
12/27/2007WO2007130672A3 Urodilatin cancer treatment
12/27/2007WO2007126941A3 Solid support reagents for synthesis
12/27/2007WO2007125226A3 Peptides modulating the activity of macrophages, useable for the treatment of rheumatoid arthritis
12/27/2007WO2007122424A3 Larval polypeptides having a nuclease activity
12/27/2007WO2007118017A3 Method for preventing increases in postoperative intraocular pressure
12/27/2007WO2007112357A3 Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
12/27/2007WO2007109118A9 RECOMBINANT HUMAN CC 10 (rhCC10) FOR TREATMENT OF RESPIRATORY DISORDERS
12/27/2007WO2007106494A3 Methods and compositions for treatment of diastolic heart failure
12/27/2007WO2007101161A8 Methods and compositions for the treatment of gastrointestinal disorders
12/27/2007WO2007091078A3 Polypeptide conjugate comprising hla-g and uses thereof, stem cells transfected with hla-g
12/27/2007WO2007081680A3 Microrna expression abnormalities in pancreatic endocrine and acinar tumors
12/27/2007WO2007069249A9 Toxin-like polypeptides, polynucleotides encoding same and uses thereof
12/27/2007WO2007024700A8 Exendin for treating diabetes and reducing body weight
12/27/2007WO2006135382A3 Enzymatic activities in chemokine-mediated inflammation
12/27/2007WO2006091231A3 Biosynthetic polypeptides utilizing non-naturally encoded amino acids
12/27/2007WO2006084139A8 An implantable interferon-containing device
12/27/2007WO2006052668A3 Induction of antigen specific immunologic tolerance
12/27/2007WO2006033024A3 Method for maximizing efficacy and predicting and minimizing toxicity of calcineurin inhibitor compounds
12/27/2007WO2005094314A3 Modulators of shp2 tyrosine phosphatase and their use in the treatment of body weight disorders
12/27/2007WO2005069859A3 Compositions and methods for modulating dhr96
12/27/2007WO2005044200A3 Methods and compositions for treating mcp-1 related pathologies
12/27/2007WO2003066824A3 Albumin-fused kunitz domain peptides
12/27/2007US20070299536 Collagen Mimics
12/27/2007US20070299390 Needleless syringe using supersonic gas flow for particle delivery
12/27/2007US20070299385 Device for the controlled exposure of reservoir-based sensors
12/27/2007US20070299247 Heterodimeric human cytokine receptor comprising interleukin-10 or orphan receptor components for use in treatment of cell proliferative, inflammatory and immune disorders
12/27/2007US20070299059 Compostions and methods relating to novel compounds and targets thereof
12/27/2007US20070299031 Therapeutic agent for tumor of neural origin
12/27/2007US20070299026 Immunosuppressive Cytokine
12/27/2007US20070299023 P185Neu-Encoding Dna and Therapeutical Uses Thereof
12/27/2007US20070299022 Antisense Oligonucleotide to Inhibit Melanoma Inhibitory Activity Mia
12/27/2007US20070299016 Specific Antibodies for Diagnosing Heart Failure
12/27/2007US20070299015 Peptide fragments for inducing synthesis of extracellular matrix proteins
12/27/2007US20070299014 Casein hydrolyzate, process for producing the same and use thereof
12/27/2007US20070299013 Exosite-Directed Thrombin Inhibitors
12/27/2007US20070299012 Method of preventing progression of hypertension-induced heart failure with PKC peptides
12/27/2007US20070299011 Appoptosin and uses thereof for treating neurodegenerative disease and cancer
12/27/2007US20070299010 CPG15 and CPG15-2 compounds and inhibitors as insulin receptor and insulin-like growth factor receptor agonists and antagonists
12/27/2007US20070299009 Analogs of parathyroid hormone
12/27/2007US20070299008 Transport Protein Which Is Used To Introduce Chemical Compounds Into Nerve Cells
12/27/2007US20070299007 Muteins OF Fibroblast Growth Factor 21
12/27/2007US20070299006 Secreted by yeast; storage stability; nonimmunogenic; vaccine; long half-life; use for growth hormone deficiency in human or animal to stimulate meat production
12/27/2007US20070299005 Family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof
12/27/2007US20070299004 Methods of providing therapeutic effects using cyclosporin compontnts
12/27/2007US20070299003 Composition Comprising a Pulmonary Surfactant and a Tnf-Derived Peptide
12/27/2007US20070299002 Glucosidase inhibitors; for lowering blood glucose levels and treatment of chronic inflammation
12/27/2007US20070299001 PURIFIED hCG
12/27/2007US20070299000 Method of lowering body fat percentage or inhibiting body fat percentage increase
12/27/2007US20070298999 Method for treating pain with a calmodulin inhibitor
12/27/2007US20070298998 Biomarkers for amyotrophic lateral sclerosis and methods using the same
12/27/2007US20070298997 Compounds useful in treating diabetic microvascular complications and age-related macular degeneration
12/27/2007US20070298996 penile erectile dysfunction; administering a coiled-coil domain of cartilage oligomeric matrix protein linked to a Tie2 receptor binding domain which is a fibrinogen-like domain of angiopoietin-1
12/27/2007US20070298493 Transgenic animal cells containing endotheilial growth factor polypeptide for use as model system for treatment of cardiovascular and respiratory system disorders
12/27/2007US20070298463 Variants of human glycoprotein hormone alpha chain: compositions and uses thereof
12/27/2007US20070298460 Novel receptor that causes cell death
12/27/2007US20070298459 Death Domain Containing Receptor 6; severe combined immunodeficiency (SCID); adenosine deaminase deficiency, agammaglobulinemia Bruton's disease
12/27/2007US20070298424 Nucleic acids and corresponding proteins entitled 273P4B7 useful in treatment and detection of cancer
12/27/2007US20070298123 Anti-angiogenic compositions and methods of use
12/27/2007US20070298117 Compositions and kits comprising a melatonin component and a chondroprotective component
12/27/2007US20070298116 Amorphous, spray-dried powders having a reduced moisture content and a high long term stability
12/27/2007US20070298104 Cyanoisoquinoline compounds and methods of use thereof
12/27/2007US20070298076 Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
12/27/2007US20070298071 Bioactive scaffold for therapeutic and adhesion prevention applications
12/27/2007US20070298066 Biodegradable linkers for molecular therapies
12/27/2007US20070298051 Adjuvants Of Immune Response
12/27/2007US20070298049 Therapeutic Agent for Polycystic Ovary Syndrome (Pcos)
12/27/2007US20070298043 Novel Antibacterial Agents and Methods of Identifying and Utilizing Same
12/27/2007US20070298037 administering antagonist to ztnfr14 comprising antibodies, antibody fragments, proteins or polypeptides, for the treatment of psoriasis, inflammatory bowel disease or multiple sclerosis in mammals
12/27/2007US20070298036 PRO71238 Polypeptides
12/27/2007US20070298032 Proteins Involved In Quorum Sensing
12/27/2007US20070298031 Methods for preventing or treating neuromuscular or muscular conditions by peripherally administered erythropoietin
12/27/2007US20070298029 Treatment of Neurodegenerative Diseases by the Use of Degs Inhibitors
12/27/2007US20070298028 Diagnostics and Therapeutics for Diseases Associated With Kallikrein 3 (Klk3)
12/27/2007US20070298027 Novel Target for Antiderpressant Therapy
12/27/2007US20070298025 Pharmaceutical Compositions and Methods for Reducing Body Fat
12/27/2007US20070298024 C-1 inactivator inhibits two-chain urokinase mutant and limits hemostatic bleeding during thrombolysis
12/27/2007US20070298023 C-1 inhibitor prevents non-specific plasminogen activation by a prourokinase mutant without impeding fibrin-specific fibrinolysis
12/27/2007US20070298022 Identification of Phospholipase A2 as Target in Cancer Treatment, with Special Emphasis on Colorectal Cancer and Its Mechanism of Action
12/27/2007US20070298021 Methods and Compositions for the Treatment or Prevention of Secondary Ischemic Injury
12/27/2007US20070298010 For reducing aggregation or immunogenicity of peptide or polypeptide including an alkylglycoside, especially dodecyl maltoside, tridecyl maltoside, sucrose monododecanoate, sucrose monotridecanoate, or sucrose monotetradecanoate; treatment of obesity
12/27/2007US20070298009 protect neural cells from degeneration and/or death in response to traumatic brain injury or autoimmune disorders of the brain, such as multiple sclerosis and in reducing seizures; hypoxia/ischemia, toxic injury, and chronic neurodegenerative disorders including Parkinson's disease
12/27/2007US20070297999 Kit containing an acidic composition and a composition based on a hydroxyalkyl urea
12/27/2007US20070297991 Neural conduit agent dissemination for smoking cessation and other applications
12/27/2007US20070297986 Screening methods for identifying agents useful for treating or reducing visual impairment in mammals
12/27/2007US20070297984 Inhibition of HIF-1 activation for anti-tumor and anti-inflammatory responses
12/27/2007US20070297982 Preparation And Composition Of Inter-Alpha Inhibitor Proteins From Human Plasma For Therapeutic Use
12/27/2007US20070297981 Formulations and methods for treating dry eye
12/27/2007US20070297979 Pharmaceutical Compounds
12/27/2007DE4240430B4 Stabilisiertes pharmazeutisches Mittel, enthaltend einen HMG-CoA-Reduktase-Inhibitor Wirkstoff A stabilized pharmaceutical composition comprising an HMG-CoA reductase inhibitor active agent
12/27/2007DE202007012343U1 Aminosäure-Mineral-Peptid-Komplex, insbesondere quantenmechanisch modifiziert, als Rezeptur zur Regulierung der Haut Amino acid-mineral-peptide complex, in particular quantum-mechanically modified, as formulation for regulating skin
12/27/2007DE102005063438A1 Verfahren zur Herstellung von porösen Schwämmen aus gereinigtem marinem Kollagen A process for producing porous sponges of purified marine collagen
12/27/2007DE10196235B4 Using collagen from aquatic animals as carriers for tissue engineering, useful e.g. as skin replacements and in screening for antiaging drugs
12/27/2007CA2826738A1 Polynucleotides and polypeptide sequences involved in cancer
12/27/2007CA2714867A1 Non-aggregated pharmaceutically active peptide
12/27/2007CA2659691A1 Modified beta-lactamase and method for its preparation
12/27/2007CA2657213A1 Peptide epoxyketones for proteasome inhibition